Endobronchial Valve (Zephyr) Treatment in Homogeneous Emphysema: One-Year Results from the IMPACT Randomized Clinical Trial
<b><i>Rationale:</i></b> The long-term safety and effectiveness of bronchoscopic lung volume reduction with Zephyr endobronchial valves in subjects with severe homogeneous emphysema with little to no collateral ventilation beyond 3 months have yet to be established. <b><i>Methods:</i></b> Ninety-three subjects were randomized to either bronchoscopic lung volume reduction with Zephyr valves or standard of care (SoC) (1:1). Zephyr valve subjects were assessed at 3, 6, and 12 months. SoC subjects were assessed at 3 and 6 months; they were then offered crossover to Zephyr valve treatment. <b><i>Results:</i></b> The mean group difference (Zephyr valve – SoC) for change in FEV<sub>1</sub> from baseline to 6 months was 16.3 ± 22.1% (mean ± SD; <i>p</i> < 0.001). Secondary outcomes showed the mean between-group difference for the six-minute walk distance of +28.3 ± 55.3 m (<i>p</i> = 0.016); St. George’s Respiratory Questionnaire, −7.51 ± 9.56 points (<i>p</i> < 0.001); modified Medical Research Council, −0.42 ± 0.81 points (<i>p</i> = 0.019); BODE index, −0.85 ± 1.39 points (<i>p</i> = 0.006); and residual volume of −430 ± 830 mL (<i>p</i> = 0.011) in favor of the Zephyr valve group. At 6 months, there were significantly more responders based on the minimal clinically important difference for these same measures in the Zephyr valve versus the SoC group. The clinical benefits were persistent at 12 months. The percentage of subjects with respiratory serious adverse events was higher in the Zephyr valve group compared to SoC during the first 30 days post-procedure but not statistically different for the Zephyr valve and SoC groups from 31 days to 6 months, and stable in the Zephyr valve group out to 12 months. There were 2 deaths in the SoC group in the 31-day to 6-month period and none in the Zephyr valve group out to 12 months. <b><i>Conclusions:</i></b> Bronchoscopic lung volume reduction with Zephyr valves in subjects with severe homogeneous emphysema and little to no collateral ventilation provides clinically meaningful change from baseline in lung function, quality of life, exercise capacity, dyspnea, and the BODE index at 6 months, with benefits maintained out to 12 months.
